Melanoma
Also known as: Metastasis, Metastases, Metastatic, Mets, Nodule
Methodology & AI Transparency ⓘ
Melanoma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Melanoma is the most serious type of skin cancer .
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C43.9 for Melanoma clinical workups.
- 3 Typical cash cost range: Clinicians assessing Melanoma focus on tumor-suppressor loss enabling in Melanoma (C43.9: clonal proliferation) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Melanoma monitoring tracks Complete Blood Count in Melanoma (C43.9: (ANC, Hemoglobin, Platelets)) toward Safe hematologic reserve (C43.9).
Ask our AI Specialists anything about Melanoma
What Is Melanoma?
Melanoma is the most serious type of skin cancer . Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or "ugly looking." Thinking of "ABCDE" can help you remember what to watch for: Asymmetry - the shape of one half does not match the other Border - the edges are ragged, blurred or irregular Color - the color is uneven and may include shades of black, brown and tan Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months Surgery is the first treatment of.
Pathophysiology, Underlying Causes & Clinical Presentation
In Melanoma (C43.9), physiological disruption stems from tumor-suppressor loss enabling in Melanoma (C43.9: clonal proliferation), Cross-referenced with NIH MeSH (Melanoma), informing Cancer, Oncology & Supportive Care protocols that track Comprehensive Metabolic & in Melanoma (C43.9: Organ Function Panel) (Preserved renal/hepatic clearance (C43.9)).
Common Symptoms & Clinical Signs
- • Asymmetry - the shape of one half does not match the other
- • Border - the edges are ragged, blurred or irregular
- • Presentation of Melanoma (C43.9): unintended weight loss [Melanoma C43.9]
- • Secondary Melanoma clinical sign: unexplained bleeding, chronic in Melanoma (C43.9: hoarseness/cough, or progressive)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Melanoma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C43.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Melanoma (C43.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C43.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Melanoma (C43.9: Organ Function Panel) | Preserved renal/hepatic clearance (C43.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Melanoma (C43.9: Genomic Staging) | Guideline-concordant surveillance (C43.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Melanoma
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Encorafenib Braftovi • RxCUI 2049119 | FDA Prescription Therapeutic Agent | 94% | $2.5500 | $ 111.78 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Melanoma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Association between metformin therapy and risk of gynecological cancer in: What a 1,710,080-Participant Study Found The results suggested the metformin can be used as a potential anticarcinogenic drug for gynecological cancers' prevention, especially for Asians and cervical cancer. European journal of obstetrics, gynecology, and reproductive biology • 2019-06-15 • Meta-Analysis | N = 1,710,080 | 94/100 | PMID 31009857 ↗ |
| Can This Approach Help? Inside the Latest Research on Role of triple therapy and therapy sequence in treatment of BRAF-mutant Current data advices for immunotherapy based regiments in patients with BRAF mutant melanoma or, possibly, sandwich approach. Journal of translational medicine • 2023-08-05 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37543586 ↗ |
| Can This Approach Help? Inside the Latest Research on Prognostic value of patient-reported outcomes in advanced or metastatic melanoma PROs at baseline and during treatment, particularly for physical functioning, GHS/QoL, fatigue, and EQ-VAS, were prognostic of survival outcomes. European journal of cancer (Oxford, England : 1990) • 2024-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39520835 ↗ |
| Can This Approach Help? Inside the Latest Research on Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Analyses involving two large phase III trials investigating adjuvant IO treatment for resected melanoma demonstrate higher cure rates for both NIVO and IPI than placebo, with NIVO providing the highest cure rate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2025-03-10 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39378385 ↗ |
| Can This Approach Help? Inside the Latest Research on Patient-reported outcomes with adjuvant nivolumab versus placebo after complete Patients with resected stage IIB/C melanoma treated with adjuvant nivolumab demonstrated stable HRQoL and minimal bother from side effects. European journal of cancer (Oxford, England : 1990) • 2025-05-02 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40139004 ↗ |
Melanoma Patient Community & “People Like Me” Threads
Filter Melanoma community threads and patient logs by age, biological sex, dosage, and treatment duration.